BRIDGEBIO PHARMA, INC.

Lobbying for BRIDGEBIO PHARMA, INC. · Biotech company

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Expenses

$270,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 6

HR 1262
Mikaela Naylon Give Kids a Chance Act
HR 1414
Cameron’s Law
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 4317
PBM Reform Act of 2025
HR 1532
Scientific EXPERT Act of 2025
S 822
Scientific EXPERT Act of 2025

Lobbying activity 1

Pharmacy

Give Kids a Chance Act of 2025 - H.R. 1262; S 932 Camerons Law - H.R. 1414 Tax Provisions in H.R. 1 - One Big Beautiful Bill Act - R&D tax credit, bonus depreciation, interest deduction Provisions related to PBM Reform in H.R. 1 - One Big Beautiful Bill Act PBM Reform Act - H.R. 4317 ORPHAN Cures Act - included in H.R. 1 - One Big Beautiful Bill Act Orphan drug policies Scientific EXPERT Act of 2025 - H.R. 1532; S. 822

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.